COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now–New Hopes?
The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the addition of interferon β-1a; remdesivir. The tri...
Main Author: | Jean Jacques Vanden Eynde |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/7/664 |
Similar Items
-
Battling COVID-19: using old weapons for a new enemy
by: Rohit Kumar, et al.
Published: (2020-05-01) -
COVID-19: An Update about the Discovery Clinical Trial
by: Jean Jacques Vanden Eynde
Published: (2020-05-01) -
COVID-19: A Brief Overview of the Discovery Clinical Trial
by: Jean Jacques Vanden Eynde
Published: (2020-04-01) -
Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19)
by: Abhi Bhadra, et al.
Published: (2020-05-01) -
Evaluation of the efficacy and safety of oral N‐acetylcysteine in patients with COVID‐19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial
by: Najmolsadat Atefi, et al.
Published: (2023-11-01)